With profits lagging, Emma Walmsley, Big Pharma's only woman CEO, may once again be its lowest paid
February’s earnings weren’t kind to GlaxoSmithKline. Not only had the UK drugmaker’s sales dropped amid the pandemic, but their years-long R&D pivot was going through a slog. They announced a series of significant setbacks leading up to earnings and then a handful of smaller ones in the earnings itself.
Those struggles have now taken an (admittedly modest) toll on their CEO, Emma Walmsley. GSK revealed in its annual report that her annual pay, most of which is tied up in stock, had fallen, from around $10.85 million in 2019 to $9.7 million in 2020.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.